Peer-reviewed veterinary case report
Canine-specific albumin treatment for low protein in dogs with septic
By Craft, Elise M & Powell, Lisa L·Published in Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001)·2012·Department of Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: The use of canine-specific albumin in dogs with septic peritonitis.
- Species:
- dog
Plain-English summary
A group of 14 dogs with low protein levels (hypoalbuminemia) after surgery for septic peritonitis (a serious abdominal infection) received a special dog-specific protein treatment called canine-specific albumin. Within two hours of receiving this treatment, the dogs showed significant improvements in their protein levels and blood pressure compared to those who did not receive it. The benefits of the treatment continued for at least 24 hours, and while one dog had breathing problems during the transfusion and later passed away, there were no other reported issues from the treatment. Overall, the use of canine-specific albumin appeared to help these dogs recover better after their surgery.
People also search for: dog septic peritonitis treatment · hypoalbuminemia in dogs · canine-specific albumin benefits
Abstract
OBJECTIVE: To assess changes in serum albumin concentration (ALB), colloid osmotic pressure (COP), and Doppler blood pressure (DBP) following transfusion of 5% lyophilized canine-specific albumin (CSA) in hypoalbuminemic dogs following surgical source control for septic peritonitis. DESIGN: Prospective randomized clinical trial November 2009 - November 2010. SETTING: University teaching hospital. ANIMALS: Fourteen client-owned dogs with hypoalbuminemia (<27 g/L [2.7 g/dL]) following surgical source control for septic peritonitis. INTERVENTIONS: Dogs were randomized to clinician-directed therapy (CDT) and CSA groups. Dogs enrolled in the CSA group received 800 mg/kg of CSA within 24 hours following surgical intervention. MEASUREMENTS AND MAIN RESULTS: At enrollment, ALB, COP, and DBP were not different between groups. ALB, COP, and DBP were significantly increased in the CSA group 2 hours following completion of the transfusion compared with the CDT group (P = 0.0234, 0.0078, 0.0156, respectively). In comparison to the CDT group, there was a significant change in ALB in the CSA group 24 hours after transfusion (P = 0.0039), but no difference in COP (P = 0.3914) or DBP (P = 0.5145). ALB was significantly higher in the CSA group at 24 hours compared with the CDT group (P = 0.0367) At the time of death or discharge, there was no difference between groups regarding ALB, COP, or DBP, but an association between ALB and survival was identified (P = 0.0273). One dog experienced tachypnea during transfusion of CSA; this dog died of unknown respiratory causes 120 hours after transfusion. CONCLUSIONS: The administration of CSA in dogs with septic peritonitis results in an increase in ALB, COP, and DBP 2 hours after administration. An increase in ALB persisted at 24 hours compared with a CDT group. Administration of this product was not associated with owner-reported delayed adverse events in this population of dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/23216837/